Method for determining prognosis of HIV infected individuals
AssigneeNeovacs
InventorsDaniel Zagury, Jean-Francois Zagury
Life of this patent
Estimating the term…
Abstract
The serum levels of anti-tat antibodies, tat protein, and p24 protein are predictive of disease progression in HIV infected individuals and serve as prognostic markers. The present invention relates to a method for determining the prognosis of an HIV infected individual by measuring serum levels of one or more of these prognostic markers. In addition, a method for monitoring whether an HIV infected individual is in need of immunization with a tat vaccine and a method for monitoring the efficacy of immunization with a tat vaccine are also disclosed.
Claims2
A method for determining the prognosis of an HIV infected individual, comprising:
- measuring the levels of anti-tat antibodies and p24 protein in the serum of an HIV infected individual;
- comparing the measured levels to a mean anti-tat antibody value and a mean p24 protein value;
- and
- determining the prognosis of the HIV infected individual, wherein anti-tat antibody levels above the mean value in combination with p24 protein levels below the mean value is indicative of disease non-progression towards AIDS, and anti-tat antibody levels below the mean value in combination with p24 protein levels above the mean level is indicative of disease progression towards AIDS.
Dependencies are inferred from the claim text.